The safety and cost of Gelofusine as a replacement fluid in therapeutic plasma exchange procedures – Feedback from low/middle-income countries

Key Points

• Gelofusine serves as a cost-effective alternative for replacement fluid in plasma exchange procedures, supporting safety and reliability.
• Key evidence shows that Gelofusine significantly reduces complications compared to other fluids in low-income settings.
• Assessment using observational data across multiple low and middle-income countries highlights varied adoption of Gelofusine.
• Findings suggest that considering Gelofusine may enhance therapeutic plasma exchange practices, particularly where resources are limited.